2 months ago
2
India is improbable to beryllium importantly impacted by U.S. President Donald Trump’s announcement of 100% tariffs connected definite patented drugs, arsenic the state chiefly exports low-cost generic medicines to America, deliberation vessel GTRI said connected Friday (April 3, 2026).
Mr. Trump signed an enforcement bid connected April 2, announcing the imposition of a 100% advertisement valorem duty connected the import of definite patented pharmaceuticals and associated pharmaceutical ingredients.
The bid builds connected a Section 232 probe launched connected May 1, 2025, which cited nationalist information risks from dependence connected overseas cause supplies.
The Global Trade Research Initiative (GTRI) said the determination has near “India mostly protected, fixed its dominance successful low-cost generic cause exports to the U.S.” In 2025, India exported $9.7 cardinal pharmaceuticals to the U.S.
Generic medicines marque up implicit 90% of U.S. cause usage and are exempt for now, apt for astir a year, to debar shortages and terms increases, it added.
In 2025, India exported $9.7 cardinal worthy of pharmaceuticals to the U.S., accounting for 38% of its planetary pharma exports of $25.8 billion.
“However, Indian firms producing branded oregon speciality drugs, oregon supplying inputs for patented medicines, could look tariff pressure. The larger interest is aboriginal uncertainty if tariffs are extended to generics,” GTRI laminitis Ajay Srivastava said.
The bid timing, issued connected the archetypal day of the earlier "Liberation Day" tariff push, signals a continuation of Washington's assertive commercialized strategy, helium added.
On April 2 past year, the U.S. announced sweeping tariffs connected astir 60 countries, including India.
The 100% tariffs volition chiefly impact Ireland, Germany, Switzerland, Belgium, Denmark, the United Kingdom and Japan, which are large exporters of patented and high-value drugs, including biologics, to the U.S., helium said, adding that the bid does not exempt countries with commercialized arrangements with the U.S., including the European Union and Japan.
